Biora Therapeutics Appoints Dr. Ariella Kelman as Chief Medical Officer
Retrieved on:
Monday, May 1, 2023
(Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the appointment of Ariella Kelman, MD, as Chief Medical Officer.
Key Points:
- (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the appointment of Ariella Kelman, MD, as Chief Medical Officer.
- Dr. Kelman has a proven track record of leading global biopharmaceutical development, clinical trials, and regulatory strategies.
- I’m looking forward to rapidly advancing the NaviCap platform into the clinic.”
Before joining Biora Therapeutics, Dr. Kelman led clinical development at Human Immunology Biosciences, a clinical-stage company focused on drug discovery and development for immune-mediated conditions. - Previously, Dr. Kelman served for ten years as an attending physician in the Division of Immunology and Rheumatology at Stanford University Hospital.